Former Madrigal executive alleges cover-up of liver drug safety issues
Former Madrigal executive alleges cover-up of liver drug safety issues
Former Madrigal executive alleges cover-up of liver drug safety issues
Key points
اہم نکات
मुख्य बातें
- A former top executive at Madrigal Pharmaceuticals has filed a federal whistleblower lawsuit alleging the company covered up safety concerns about Rezdiffra, its approved treatment for the liver disease MASH.
- Michael Charlton, the company's former head of clinical development, says he was forced to resign in January 2026 after raising concerns about liver-injury data and clinical-trial reporting.
- Madrigal disputes the allegations and says it will defend itself vigorously; the case was disclosed in its third-quarter securities filing.
- A former top executive at Madrigal Pharmaceuticals has filed a federal whistleblower lawsuit alleging the company covered up safety concerns about Rezdiffra, its approved treatment for the liver disease MASH.
- Michael Charlton, the company's former head of clinical development, says he was forced to resign in January 2026 after raising concerns about liver-injury data and clinical-trial reporting.
- Madrigal disputes the allegations and says it will defend itself vigorously; the case was disclosed in its third-quarter securities filing.
- A former top executive at Madrigal Pharmaceuticals has filed a federal whistleblower lawsuit alleging the company covered up safety concerns about Rezdiffra, its approved treatment for the liver disease MASH.
- Michael Charlton, the company's former head of clinical development, says he was forced to resign in January 2026 after raising concerns about liver-injury data and clinical-trial reporting.
- Madrigal disputes the allegations and says it will defend itself vigorously; the case was disclosed in its third-quarter securities filing.
A former top executive at Madrigal Pharmaceuticals has filed a federal whistleblower lawsuit alleging the company covered up safety concerns about Rezdiffra, its approved treatment for the liver disease MASH. Michael Charlton, the company's former head of clinical development, says he was forced to resign in January 2026 after raising concerns about liver-injury data and clinical-trial reporting. Madrigal disputes the allegations and says it will defend itself vigorously; the case was disclosed in its third-quarter securities filing.
A former top executive at Madrigal Pharmaceuticals has filed a federal whistleblower lawsuit alleging the company covered up safety concerns about Rezdiffra, its approved treatment for the liver disease MASH. Michael Charlton, the company's former head of clinical development, says he was forced to resign in January 2026 after raising concerns about liver-injury data and clinical-trial reporting. Madrigal disputes the allegations and says it will defend itself vigorously; the case was disclosed in its third-quarter securities filing.
A former top executive at Madrigal Pharmaceuticals has filed a federal whistleblower lawsuit alleging the company covered up safety concerns about Rezdiffra, its approved treatment for the liver disease MASH. Michael Charlton, the company's former head of clinical development, says he was forced to resign in January 2026 after raising concerns about liver-injury data and clinical-trial reporting. Madrigal disputes the allegations and says it will defend itself vigorously; the case was disclosed in its third-quarter securities filing.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।